Data in this study cohort indicated that CEA, CA199, and CA125 were not effective in HCC diagnosis, but interestingly, CA199, an aberrant glycosylation marker [24, 43], had a positive rate of 69.57% in this retrospective cohort of ICC patients, much higher than DCP and AFP (Table S4). This evidence concerns the gene CEACAM5 and intrahepatic cholangiocarcinoma.